Analyst Price Targets — GNFT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2024 6:39 am | Ed Arce | H.C. Wainwright | $13.00 | $5.03 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Genfit (GNFT) |
Latest News for GNFT
Lille, France; Cambridge, MA; Zurich, Switzerland; April 2, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2025 and provided a corporate update. A summary of the consolidated financial statements is included below.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new…
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GNFT.
Senate Trading
No Senate trades found for GNFT.
U.S. House Trading
No House trades found for GNFT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.